Key Takeaways
- Ion mobility spectrometry (IMS) advances are providing higher‑resolution gas‑phase separations that reveal subtle conformational differences in proteins.
- Functional proteomics is moving beyond static abundance measurements to capture activity‑state changes, post‑translational modifications, and interaction networks in near‑real time.
- AI‑enabled data analysis platforms are turning massive, multidimensional proteomics datasets into interpretable biological insights, reducing the bottleneck between data generation and hypothesis testing.
- Integrated workflows that couple IMS, high‑resolution mass spectrometry, and automated sample preparation are enabling reproducible, high‑throughput studies of protein structure‑function relationships.
- These technologies collectively empower researchers to link molecular shape and dynamics directly to cellular function, accelerating drug discovery and basic biomedical research.
Interview Context and Motivation
At ASMS 2026, the Technology Networks team interviewed Rohan Thakur, President of TOFWERK, MS Technologies, Innovation, and Markets at Bruker, to explore how emerging analytical tools are reshaping proteomics. Thakur emphasized that the biological community’s appetite for deeper mechanistic understanding is driving demand for platforms that not only quantify proteins but also resolve their three‑dimensional states and functional phenotypes. He noted that traditional bottom‑up proteomics, while powerful for inventorying the proteome, often loses critical structural information during enzymatic digestion. Consequently, the field is shifting toward top‑down and native‑state approaches that preserve protein integrity, coupled with rapid data‑interpretation strategies to keep pace with the exponential growth of data volume.
Ion Mobility Spectrometry: Sharpening Gas‑Phase Separation
Rohan highlighted that recent advances in ion mobility spectrometry—particularly trapped ion mobility spectrometry (TIMS) and structures for lossless ion manipulations (SLIM)—have dramatically increased resolving power and analysis speed. These platforms separate ions based on their collisional cross‑section, allowing isomers and conformers that have identical mass-to-charge ratios to be distinguished. For proteins, this means that subtle conformational shifts induced by ligand binding, phosphorylation, or oxidative stress can be detected directly in the gas phase. Thakur pointed out that the coupling of TIMS with high‑resolution Orbitrap or Fourier‑transform ion cyclotron resonance (FT‑ICR) mass spectrometers now enables routine measurement of collisional cross‑section values alongside accurate mass, providing a orthogonal dimension of structural information that was previously accessible only through low‑throughput techniques such as NMR or X‑ray crystallography.
Functional Proteomics: From Abundance to Activity
The interview also covered the evolution of functional proteomics, which aims to capture the functional state of proteins rather than merely their concentration. Rohan described new workflows that integrate activity‑based protein profiling (ABPP), limited proteolysis coupled to mass spectrometry (LiP‑MS), and cross‑linking MS to map enzyme active sites, protease susceptibility, and protein‑protein interaction interfaces under native conditions. By preserving non‑covalent interactions during sample preparation—using gentle lysis buffers, rapid quenching, and online desalting—these methods retain transient complexes and conformational ensembles that are lost in traditional denaturing workflows. Thakur stressed that functional readouts, such as changes in protease accessibility or ligand‑induced protection patterns, provide direct readouts of protein function, enabling researchers to correlate structural perturbations with phenotypic outcomes in disease models.
AI‑Enabled Data Analysis: Making Sense of Multidimensional Data
A major bottleneck in modern proteomics is the sheer volume and complexity of data generated when IMS, high‑resolution MS, and functional assays are combined. Rohan explained that Bruker’s recent AI‑driven software suites employ deep learning models trained on large libraries of experimental and simulated spectra to perform automated peak picking, deconvolution, and cross‑technical feature alignment. These models can predict collisional cross‑section from sequence alone, assign post‑translational modifications with high confidence, and flag anomalous patterns indicative of novel isoforms or degradation products. Moreover, unsupervised clustering algorithms reveal hidden subpopulations of protein species that correlate with specific cellular states, guiding hypothesis generation without user bias. Thakur noted that the integration of explainable AI (XAI) modules helps scientists understand why a particular feature was highlighted, fostering trust and facilitating mechanistic interpretation.
Gas‑Phase Separation Technologies: Enabling Native‑State Analysis
Beyond IMS, Rohan discussed innovations in gas‑phase ion manipulation that extend the analytical window for large, labile biomolecules. Techniques such as cryogenic ion spectroscopy and ultraviolet photodissociation (UVPD) coupled to IMS enable site‑specific fragmentation while preserving non‑covalent interactions, providing structural restraints akin to those obtained from solution‑phase experiments. He highlighted that the implementation of dual‑pressure linear ion traps and traveling‑wave ion mobility (TWIM) devices allows for the separation of mega‑Dalton complexes—such as ribosomes, viral capsids, and protein assemblies—without loss of integrity. These capabilities are crucial for studying macromolecular machines where subunit composition and arrangement dictate function, and they bridge the gap between top‑down proteomics and structural biology.
Workflow Automation and Reproducibility
Thakur underscored that technological breakthroughs only translate into scientific progress when embedded in robust, automated workflows. Bruker’s latest platforms integrate online sample preparation—including automated digestion, labeling, and enrichment—with liquid chromatography, IMS, and MS acquisition under unified software control. This end‑to‑end automation minimizes manual handling, reduces variability, and increases throughput to hundreds of samples per day. Moreover, the use of standardized calibration scripts and real‑time quality‑control metrics ensures that collisional cross‑section values and mass accuracies remain consistent across runs and laboratories. Rohan argued that such reproducibility is essential for multi‑center studies, clinical biomarker validation, and regulatory submissions where data comparability is paramount.
Connecting Protein Structure to Function
The core message of the interview was that the synergy of enhanced gas‑phase separation, functional proteomics readouts, and AI‑driven interpretation now enables a direct line of evidence from protein shape to biological activity. For example, a drug‑induced conformational shift detected by a change in ion mobility arrival time can be coupled with LiP‑MS data showing altered protease susceptibility at a specific loop, while AI models predict the impact of that shift on binding affinity. This multidimensional evidence package allows researchers to move beyond correlative observations and assert causative links between structural dynamics and cellular phenotypes. Thakur illustrated this with a case study in oncology where a mutant kinase exhibited a distinct mobility signature that correlated with increased autophosphorylation and downstream signaling, ultimately informing the design of an allosteric inhibitor that restored the wild‑type mobility profile.
Market Implications and Future Directions
Looking ahead, Rohan predicted that the market for native‑state proteomics platforms will expand rapidly as pharmaceutical companies seek to characterize drug target engagement and off‑target effects at the structural level. He anticipates growth in demand for hybrid instruments that combine IMS with high‑resolution MS and complementary spectroscopic modalities (e.g., IRMPD, UVPD) within a single platform. Additionally, the rise of cloud‑based AI analytics will democratize access to sophisticated data interpretation, allowing smaller laboratories to harness the power of large datasets without investing in extensive computational infrastructure. Thakur also highlighted the need for community‑wide standards for collisional cross‑section reporting and functional proteomics assays, suggesting that collaborative efforts—similar to those that drove the development of peptide identification‑level proteomics standards—will be essential for ensuring comparability across studies.
Concluding Remarks
In closing, Rohan Thakur expressed optimism that the continued convergence of ion mobility advancements, functional proteomics strategies, and intelligent data analysis will transform how scientists interrogate the proteome. By providing a detailed, dynamic view of protein structure in its native context, these technologies empower researchers to answer longstanding questions about how molecular mechanics dictate biological function, ultimately accelerating discovery in basic science, translational research, and therapeutic development. He encouraged the audience to embrace these emerging tools, participate in standardization initiatives, and leverage the resulting insights to drive the next generation of biomedical breakthroughs.